CIK 0000872589 · Large accelerated filer
REGENERON PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- REGN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NY
- Entity type
- operating
- EIN
- 133444607
- Phone
- 9148477000
- Business address
- 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591
- Former names
- REGENERON PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $51,901,544
- in 11 filings, $8.6M under 10b5-1 plans
Net −$51,901,544. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-27 | BROWN MICHAEL S Director | Option exercise 10b5-1 | +2,049 | $482.68 | $989K | 3,296 |
| 2023-12-27 | BROWN MICHAEL S Director | Sale 10b5-1 | −2,049 | $898.00 | $1.8M | 1,247 |
| 2023-12-27 | BROWN MICHAEL S Director | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −2,049 | 0 | ||
| 2023-12-27 | Landry Robert E EVP Finance CFO | Option exercise | +750 | $378.98 | $284K | 22,111 |
| 2023-12-27 | Landry Robert E EVP Finance CFO | Shares withheld for taxes | −542 | $872.21 | $473K | 21,569 |
| 2023-12-27 | Landry Robert E EVP Finance CFO | Option exercise · Non-Qualified Stock Option (right to buy) | −750 | 18,587 | ||
| 2023-12-27 | Fenimore Christopher R. SVP Controller | Sale 10b5-1 | −2,448 | $856.71 | $2.1M | 14,372 |
| 2023-12-22 | Fenimore Christopher R. SVP Controller | Sale 10b5-1 | −250 | $846.27 | $212K | 16,820 |
| 2023-12-21 | Fenimore Christopher R. SVP Controller | Sale 10b5-1 | −456 | $843.79 | $385K | 18,294 |
| 2023-12-21 | Fenimore Christopher R. SVP Controller | Sale 10b5-1 | −1,224 | $844.09 | $1.0M | 17,070 |
| 2023-12-13 | Landry Robert E EVP Finance CFO | Option exercise | +1,000 | $378.98 | $379K | 22,084 |
| 2023-12-13 | Landry Robert E EVP Finance CFO | Shares withheld for taxes | −723 | $871.12 | $630K | 21,361 |
| 2023-12-13 | Landry Robert E EVP Finance CFO | Option exercise · Non-Qualified Stock Option (right to buy) | −1,000 | 19,337 | ||
| 2023-12-13 | Bassler Bonnie L Director | Option exercise 10b5-1 | +610 | $376.69 | $230K | 1,857 |
| 2023-12-13 | Bassler Bonnie L Director | Sale 10b5-1 | −610 | $870.00 | $531K | 1,247 |
| 2023-12-13 | Bassler Bonnie L Director | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −610 | 0 | ||
| 2023-12-12 | McCourt Marion EVP Commercial | Shares withheld for taxes | −5,105 | $856.71 | $4.4M | 15,336 |
| 2023-12-12 | MURPHY ANDREW J EVP Research | Shares withheld for taxes | −7,657 | $856.71 | $6.6M | 48,306 |
| 2023-12-12 | Fenimore Christopher R. SVP Controller | Shares withheld for taxes | −2,552 | $856.71 | $2.2M | 18,750 |
| 2023-12-12 | Landry Robert E EVP Finance CFO | Shares withheld for taxes | −6,381 | $856.71 | $5.5M | 21,084 |
Page 43 of 49 · 971 trades